Show simple item record

dc.contributor.authorNational Narcolepsy Study Steering Committee
dc.date.accessioned2013-10-15T09:25:50Z
dc.date.available2013-10-15T09:25:50Z
dc.date.issued2010
dc.identifier.urihttp://hdl.handle.net/10147/303432
dc.descriptionIn August 2010 the Swedish pharmacovigilance authority reported that it was investigating six cases of narcolepsy reported by health care professionals as a possible adverse event following the use of Pandemrix vaccine, used during the H1N1 2009 pandemic. This was followed shortly by reports from the Finnish National Institute for Health and Welfare (THL) noting there had been a more than expected number of cas es of narcolepsy in children and adolescents that year. On 23rd September, the Committee on Human Medicinal Products (CHMP) of the EMA concluded in its initial re view of available data that the available evidence did not confirm a link but that more research was neededen_GB
dc.language.isoenen
dc.publisherHSE Health Protection Surveillance Centre (HPSC)en_GB
dc.subjectSLEEP DISORDERen_GB
dc.subjectIMMUNISATIONen_GB
dc.subjectYOUNG PEOPLEen_GB
dc.titleInvestigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010en_GB
dc.typeReporten
refterms.dateFOA2018-08-23T08:35:51Z


Files in this item

Thumbnail
Name:
File13379.pdf
Size:
1.073Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record